Skip to main content
. 2023 May 19;151:e128. doi: 10.1017/S0950268823000717

Table 2.

Differences in demographics between COVID-19 patients with a duration of viral shedding ≤14 days and > 14 days in the developmental and validation datasets

Developmental dataset (local patients) Validation dataset (overseas patients)
DVS ≤14 days >14 days P value ≤14 days >14 days P value
Age, years 36.0 (29.0, 45.0) 40.0 (30.0, 53.0) 0.017 42.5 (34.5, 55.5) 57.0 (46.0, 62.0) 0.003
Sex 0.955 0.033
Male, n 112 (57.4%) 82 (57.7%) 40 (71.4%) 33 (91.7%)
Female, n 83 (42.6%) 60 (42.3%) 16 (28.6%) 3 (8.3%)
Days since onset, days 0.0 (0.0, 1.0) 0.5 (0.0, 1.0) 0.353 1.0 (0.0, 1.0) 1.0 (0.0, 1.0) 0.581
Comorbidities
Hypertension, n 12 (6.2%) 12 (8.5%) 0.418 10 (17.9%) 11 (30.6%) 0.157
Diabetes, n 7 (3.6%) 8 (5.6%) 0.369 7 (12.5%) 8 (22.2%) 0.218
Use of ACEIs/ARBs 7 (3.6%) 4 (2.8%) 0.766 5 (8.9%) 1 (2.8%) 0.398
COVID-19 vaccine doses 0.315 0.109
0 doses, n 9 (4.6%) 9 (6.3%) 5 (8.9%) 0 (0.0%)
1 dose, n 2 (1.0%) 5 (3.5%) 1 (1.8%) 1 (2.8%)
2 doses, n 79 (40.5%) 50 (35.2%) 18 (32.1%) 7 (28.0%)
3 doses, n 105 (53.8%) 78 (54.9%) 32 (57.1%) 28 (77.8%)
Symptomatic, n 111 (56.9%) 87 (61.3%) 0.424 14 (25.0%) 16 (44.4%) 0.052
Weight, kg 61.0 (55.0, 70.5) 61.0 (55.0, 72.5) 0.710 64.5 (58.0, 72.0) 69.9 (61.8, 72.5) 0.133
Height, m 1.65 (1.58, 1.70) 1.65 (1.57, 1.70) 0.425 1.67 (1.61, 1.73) 1.68 (1.65, 1.70) 0.580
BMI, kg/m2 23.31 (20.76, 25.97) 23.44 (21.51, 26.04) 0.411 22.96 (20.81, 25.30) 24.39 (21.70, 26.47) 0.148
ORF gene Ct value 25.0 (19.0, 31.0) 23.0 (18.0, 28.0) 0.018 29.0 (24.0, 33.5) 24.0 (21.0, 28.5) 0.003
N gene Ct value 25.0 (19.0, 30.0) 23.0 (18.0, 29.0) 0.014 28.0 (24.0, 33.0) 24.0 (21.0, 28.5) 0.001
WBC count, 109/L 6.01 (4.58, 7.43) 5.96 (4.87, 7.43) 0.556 6.46 (4.93, 8.60) 6.98 (5.54, 8.23) 0.707
Neutrophil count, 109/L 3.77 (2.79, 5.31) 4.25 (3.04, 5.37) 0.150 4.29 (3.01, 5.84) 4.56 (3.30, 5.80) 0.611
Lymphocyte count, 109/L 1.25 (0.84, 1.74) 1.09 (0.72, 1.52) 0.004 1.54 (1.10, 2.02) 1.41 (0.92, 1.84) 0.229
Monocyte count, 109/L 0.49 (0.38, 0.63) 0.49 (0.35, 0.62) 0.823 0.48 (0.37, 0.62) 0.51 (0.43, 0.59) 0.218
NLR 3.02 (1.86, 5.10) 3.54 (2.30, 7.32) 0.006 2.76 (1.81, 4.37) 3.27 (2.12, 4.87) 0.183
CRP, mg/L 2.80 (0.90, 5.77) 4.25 (1.40, 9.10) <0.001 1.00 (0.10, 3.65) 3.05 (1.03, 8.85) 0.002
K+, mmol/L 3.97 (3.76, 4.13) 3.82 (3.60, 3.98) <0.001 3.96 (3.76, 4.18) 3.70 (3.57, 4.03) 0.010
Cl, mmol/L 104.00 (101.85, 106.20) 103.65 (102.00, 106.00) 0.952 103.35 (101.40, 105.05) 103.55 (102.25, 106.00) 0.185
ALT, U/L 16.10 (12.05, 25.55) 15.35 (11.00, 24.30) 0.281 21.35 (14.45, 32.00) 17.00 (13.40, 22.15) 0.091
AST, U/L 19.00 (15.90, 23.70) 18.85 (16.20, 22.70) 0.756 20.60 (16.00, 23.30) 17.90 (14.55, 21.80) 0.145
ALB, g/L 46.40 (44.90, 48.40) 45.70 (43.60, 47.01) <0.001 45.90 (43.80, 48.45) 43.95 (41.50, 46.40) 0.002
Cr, μmol/L 70.00 (59.50, 81.50) 72.00 (56.00, 85.00) 0.626 77.50 (62.50, 89.00) 81.00 (74.00, 92.50) 0.098
LDH, U/L 169.00 (151.00, 189.00) 171.00 (153.00, 188.00) 0.779 169.00 (150.00, 182.00) 171.50 (150.00, 189.50) 0.908
CK, U/L 86.00 (65.00, 111.00) 88.00 (64.00, 113.00) 0.986 89.50 (75.00, 127.50) 106.50 (79.50, 155.50) 0.261
CK-MB, U/L 11.70 (9.90, 13.95) 11.75 (9.60, 14.20) 0.728 11.50 (10.10, 13.40) 12.35 (10.10, 14.35) 0.331
D-dimer, μg/mL 0.22 (0.22, 0.34) 0.22 (0.22, 0.39) 0.538 0.22 (0.22, 0.28) 0.23 (0.22, 0.31) 0.616
IL-6, μg/mL 3.61 (1.56, 7.43) 5.50 (2.47, 11.18) 0.001 2.57 (1.00, 4.62) 3.87 (1.62, 7.78) 0.066

ACEI, angiotensin converting enzyme inhibitor; ALB, albumin; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BMI, body mass index; CK, creatine kinase; CK-MB, creatine kinase-MB; Cr, serum creatinine; CRP, C-reactive protein; DVS, duration of viral shedding; LDH, lactate dehydrogenase; IL-6, interleukin-6; NLR, neutrophil-lymphocyte ratio; WBC, white blood cell.

Data are presented as the median (IQR) or n (%). P values were calculated using Wilcoxon’s rank-sum test, the χ2 test, or Fisher’s exact test.